• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
HOTH

HOTH

Hoth Therapeutics, Inc.

NASDAQHealthcareBiotechnologyUS

USD1.34

-0.12 (-8.21%)

Rating:C

Company Profile

CEO

Robb Knie

IPO Date

2019-02-15

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$1.28

Prev. Close

$1.46

Day Low

$1.17

Day High

$1.50

52W Low

$0.49

52W High

$2.20

Market Cap

$0.02B

Volume

7.28M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

48.9%

Avg Negative

1.4%

Avg Neutral

49.5%

News Feed

Hoth Therapeutics' HT-003 Shows Encouraging Action Against Acne In Animal Model

Benzinga·7/13/2021·↑ positive

Hoth Therapeutics Announces Positive Confirmatory Results from In Vivo Model of HT-003 Assets as Potential Treatment Against Acne

PRNewsWire·7/13/2021·↑ positive

Hoth Therapeutics Announces Positive Safety Results from AD001 Cohort 1 of Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis

PRNewsWire·6/28/2021·↑ positive

Hoth Therapeutics Announces Sponsored Research Agreement with Washington University for Novel Alzheimer's Therapeutic HT-ALZ

PRNewsWire·6/7/2021·↑ positive

Hoth Therapeutics Shares Positive Preclinical Results of Novel HT-KIT Therapeutic

PRNewsWire·6/3/2021·↑ positive

Hoth Therapeutics Unveils Preclinical Results of HT-KIT Therapeutic Program

Benzinga·6/3/2021·↑ positive

Hoth Therapeutics Plans Shareholder Presentation on HT-KIT Therapeutic's Preclinical Results for Rare Cancers

PRNewsWire·6/1/2021·↑ positive

Hoth Therapeutics Announces Participation at the American Society of Clinical Oncology (ASCO) Annual Meeting

PRNewsWire·5/24/2021·↑ positive

HOTH Therapeutics (NASDAQ: HOTH): Developing Life-Changing Drugs for Rare Cancers and Diseases

Benzinga·5/18/2021·↓ negative

Hoth Therapeutics Provides Shareholder Update on Novel Endocannabinoid Therapeutic for Cutaneous Lupus Erythematosus

PRNewsWire·5/13/2021·↑ positive